June 6-11, 2010
Vaccines are diverse and complex biological molecules, complexes and particles. Different production technologies are used for vaccines manufacturing and every production process require somekind of vaccine purification. Purification of vaccines is technically challenging and was traditionally inefficient and partially neglected due to different economical and technical reasons. Density gradient ultracentrifugation, introduced in1960s is still a major purification step for many vaccines present on the market. As a complementary techniques, cross flow filtration and chromatography has been used. Conventional chromatography supports designed for protein purification have relatively small pore sizes with restricted access for large molecules and viruses. In addition mass transfer in resins is based on diffusion and as such is not optimal for large molecules. An alternative to conventional resins are monoliths characterized by large flow through channels and convective mass transfer which results in a high and flow-independent dynamic binding capacity and resolution. Together with high low rates these properties enable increased productivity which makes monoliths attractive chromatographic supports for viruses and plasmid DNA purification. The presentation will focus on development and optimization of a purification processes for influenza viruses, adenoviruses, bacteriophages, and plasmid DNA. The characteristics of plasmid DNA and viruses are peculiar obstacles for chromatography and inherent limitations will be presented. Chromatography methods with an emphasis on ion exchange and hydrophobic interaction monolithic chromatography will be discussed and impact of monolith chromatography on process economic will be presented.
Matjaz Peterka, Franci Smrekar, Tony Brazzale, Marko Banjac, Petra Kramberger, Milos Barut, Ales Podgornik, and Ales Strancar, "CIM TECHNOLOGY: ENABELING ECONOMIC VACCINE PURIFICATION" in "Vaccine Technology III", John G. Auniņš,Merck, USA; Barry C. Buckland, BiologicB, USA; Kathrin U. Jansen, Pfizer, USA; Paula Marques Alves, IBET, Portugal Eds, ECI Symposium Series, (2010). http://dc.engconfintl.org/vaccine_iii/14